Financial Report: Sanofi-Aventis 2Q

Sanofi-Aventis 2Q

2Q Revenues: $10.4 billion (+11%)

2Q Earnings: $3.2 billion (+29%)

YTD Revenues: $20.4 billion (+7%)

YTD Earnings: $6.2 billion (+22%)

Comments: Pharmaceutical sales were up 7% to $9.4 billion. Lantus sales were up 26% to $1.1 billion. Lovenox sales were up 13% to $1.1 billion. Taxotere sales were $820 million (+11%). Plavix sales were up 5% to $989 million. Eloxatin sales were down 4% to $496 million. Sales in the U.S. and Europe were up 5%, and 20% in emerging markets. Human vaccine sales were down 1% to $1.0 billion. This includes $32.5 million of H5N1 vaccine sales in the U.S., compared to $192.5 million in 2Q08. Excluding H5N1 vaccine sales, 2Q sales were up 18%. *Earnings in the quarter and YTD reflect adjusted income and exclude selected items.

Sign up today for Contracting & Outsourcing 2009!
dhruv_cp.rodpub.com/2009conference